Key Segments:
By Treatment Type
-
Ursodeoxycholic Acid (UDCA)
-
Obeticholic Acid
-
Antibiotics
-
Immunosuppressants
-
Symptomatic Treatment
-
Liver Transplantation
-
Other Treatments
By Route of Administration
-
Oral
-
Intravenous
-
Other Routes
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
-
Specialty Pharmacies
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
North America dominated the primary sclerosing cholangitis (PSC) market in 2025.
The primary sclerosing cholangitis (PSC) market is expected to grow at a CAGR of 7.63% from 2026 to 2035.
The primary sclerosing cholangitis (PSC) market was valued at USD 181.66 million in 2025.
The major growth factor is increasing investment in clinical research and development of innovative, targeted therapies for PSC, addressing significant unmet treatment needs.
The oral segment dominated the primary sclerosing cholangitis (PSC) market in 2025.